Abiomed (NASDAQ: ABMD) is a pioneer and global leader in healthcare technology and innovation, with a mission of RECOVERING HEARTS AND SAVING LIVES. Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.
Type
Public
HQ
Danvers, US
Size (employees)
747 (est)+27%
ABIOMED is headquartered in Danvers, US

ABIOMED Office Locations

ABIOMED has offices in Danvers and Aachen
Danvers, US (HQ)
22 Cherry Hill Dr
Aachen, DE
3 Neuenhofer Weg

ABIOMED Metrics

ABIOMED Financial Metrics

ABIOMED's revenue was reported to be $329.5 m in 2016

Revenue (Y, 2016)

$329.5 m

Revenue growth (Y, 2015 - Y, 2016), %

43%

Net income (Y, 2016)

$38.1 m

EBIT (Y, 2016)

$65.1 m

Market capitalization (22-May-2017)

$5.9 b

Closing share price (22-May-2017)

$134.4

Cash (31-Mar-2016)

$48.2 m
ABIOMED's current market capitalization is $5.9 b.
FY, 2014FY, 2015Y, 2016

Revenue

$183.6 m$230.3 m$329.5 m

Revenue growth, %

25%43%

Gross profit

$146.3 m$190.4 m

Gross profit Margin, %

80%83%

Operating expense total

$138 m$161.7 m$264.4 m

EBIT

$8.4 m$28.7 m$65.1 m

EBIT margin, %

5%12%20%

Pre tax profit

$8.5 m$28.8 m$65.8 m

Income tax expense

$1.2 m($84.9 m)$27.7 m

Net Income

$7.4 m$113.7 m$38.1 m
FY, 2014FY, 2015FY, 2016

Cash

$20.9 m$22.4 m$48.2 m

Accounts Receivable

$24.4 m$31.8 m$42.8 m

Inventories

$13.9 m$16.8 m$26.7 m

Current Assets

$118 m$220.1 m$288.4 m

PP&E

$6.9 m$9.1 m$23.2 m

Goodwill

$38 m$31.5 m$33 m

Total Assets

$205.4 m$338.4 m$423.9 m

Accounts Payable

$7.7 m$10.4 m$9.4 m

Current Liabilities

$30.4 m$39.3 m$46.5 m

Additional Paid-in Capital

$436.1 m$465 m$508.6 m

Retained Earnings

($250.9 m)($137.2 m)($99.1 m)

Total Equity

$168.4 m$291.6 m$368.8 m

Financial Leverage

1.2 x1.2 x1.1 x
FY, 2014FY, 2015FY, 2016

Net Income

$7.4 m$113.7 m$38.1 m

Depreciation and Amortization

$2.8 m$3.3 m

Accounts Receivable

($1.3 m)($8 m)($11 m)

Inventories

($622 k)($7 m)($11 m)

Accounts Payable

($54 k)$3.4 m($2.6 m)

Cash From Operating Activities

$23.5 m$43.3 m$76.8 m

Purchases of PP&E

($2.8 m)($5.2 m)($15.6 m)

Cash From Investing Activities

($22.3 m)($49.9 m)($57.7 m)

Cash From Financing Activities

$9.6 m$9.5 m$7.2 m

Income Taxes Paid

$1.3 m$1.2 m$848 k
Y, 2016

Financial Leverage

1.1 x

ABIOMED Market Value History

ABIOMED Median Salaries

Source: 15 public H-1B filings from ABIOMED

ABIOMED Online Presence

ABIOMED News

ABIOMED Company Life

You may also be interested in